Recent Material Events

Track the latest material events (8-K filings) with AI-powered analysis. Stay informed about major corporate developments, acquisitions, and changes.

📊 1175 Events

🤖 AI Analyzed

Recent

📄 Page 97 of 98

PAVmed Inc.

8-K December 5, 2025

Key Highlights

PAVmed stockholders approved a reverse stock split and a significant reduction i...
The board of directors now has the power to implement a reverse stock split with...
The total authorized shares will be cut from 250,000,000 to 25,000,000.

Read Analysis

🤖 AI Generated

Vertiv Holdings Co

8-K December 5, 2025

Key Highlights

Vertiv Holdings Co, through its subsidiary Vertiv Corporation, acquired Purge Ri...
The acquisition involved an upfront cash payment of approximately $1.0 billion, ...
PurgeRite specializes in mechanical flushing, purging, and filtration services f...

Read Analysis

🤖 AI Generated

Co-Diagnostics, Inc.

8-K December 5, 2025

Key Highlights

Co-Diagnostics' shareholders approved a reverse stock split plan.
The Board of Directors has up to 12 months to decide the exact ratio, ranging fr...
The primary goal is to increase the stock price per share to attract institution...

Read Analysis

🤖 AI Generated

Reborn Coffee, Inc.

8-K December 5, 2025

Key Highlights

Reborn Coffee, Inc. received official notice that its stock will be delisted fro...
The delisting is primarily due to the company's failure to maintain the minimum ...
Trading of Reborn Coffee's stock on Nasdaq is scheduled to be suspended starting...

Read Analysis

🤖 AI Generated

Vivos Therapeutics, Inc.

8-K December 5, 2025

Key Highlights

Vivos Therapeutics secured a new Promissory Note (loan) of $2,093,340 from Avond...
Vivos actually received $1,500,000 in cash after upfront fees and discounts.
The loan is unsecured, guaranteed by a Vivos subsidiary (AIM), and is intended f...

Read Analysis

🤖 AI Generated

Aditxt, Inc.

8-K December 5, 2025

Key Highlights

Aditxt, Inc. received a notice from Nasdaq for failing to meet Listing Rule 5550...
The company faces potential delisting from Nasdaq if it cannot regain compliance...
Delisting would significantly hurt Aditxt's reputation, make it difficult to rai...

Read Analysis

🤖 AI Generated

Cambium Networks Corp

8-K December 5, 2025

Key Highlights

Cambium Networks avoided immediate delisting from Nasdaq Global Market but remai...
The company was in danger of delisting due to a consistently low stock price (be...
Nasdaq has given Cambium Networks a hard deadline of April 16, 2026, to file all...

Read Analysis

🤖 AI Generated

Celularity Inc

8-K December 5, 2025

Key Highlights

Celularity Inc. received a warning letter from the U.S. Food and Drug Administra...
The FDA stated that Celularity's marketing materials for Interfyl included 'outc...
While the company states the letter does not stop sales or require a product rec...

Read Analysis

🤖 AI Generated

Atai Beckley N.V.

8-K December 5, 2025

Key Highlights

Atai Beckley N.V. filed a prospectus supplement with the SEC to officially regis...
These shares were previously issued as part of the acquisition of Beckley Psytec...
The filing fulfills a legal promise (registration rights agreement) made during ...

Read Analysis

🤖 AI Generated

USCB FINANCIAL HOLDINGS, INC.

8-K December 5, 2025

Key Highlights

USCB FINANCIAL HOLDINGS, INC. sold $44.6 million in available-for-sale securitie...
The move aims to improve future earnings, drive growth in earnings per share (EP...
The company expects a one-time after-tax loss of approximately $5.6 million in t...

Read Analysis

🤖 AI Generated

INSPIRE VETERINARY PARTNERS, INC.

8-K December 5, 2025

Key Highlights

Inspire Vet lowered the 'Floor Price' for Series B Convertible Preferred Stock a...
The company redeemed approximately 2,027 Series B Preferred Stock shares for rou...
An amendment was added to Target Capital 1 LLC's loan agreement, capping their o...

Read Analysis

🤖 AI Generated

Mural Oncology plc

8-K December 5, 2025

Key Highlights

Mural Oncology plc has been acquired by XOMA Royalty Corporation, through its su...
Mural Oncology is no longer an independent public company and its stock will be ...
Shareholders will receive $2.035 in cash for each Ordinary Share.

Read Analysis

🤖 AI Generated

Stay Informed with AI Analysis

Get comprehensive insights from material event filings with our AI-powered analysis. Track corporate developments, acquisitions, and strategic changes.

Back to Homepage